BCL2L1 and breast cancer: In summary, BC200 is an ER-regulated target, raising the intriguing possibility that upregulation of BC200 in human breast tumors may play a critical role during breast cancer pathogenesis and progression by restraining apoptotic cell death owing to its ability to regulate Bcl-xL expression.